We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

12 hedge funds and large institutions have $426K invested in Cellectar Biosciences in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,080% more capital inflows, than outflows

Capital inflows: $249K | Capital outflows: $21.1K

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

20% more funds holding

Funds holding: 10 → 12 (+2)

1.21% more ownership

Funds ownership: 3.11% → 4.32% (+1.2%)

Holders
12
Holders Change
+2
Holders Change %
+20%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
+$98.2K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$73.7K
3
Citadel Advisors
Citadel Advisors
Florida
+$58.3K
4
Iron Gate Global Advisors
Iron Gate Global Advisors
Utah
+$15.4K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.07K

Top Sellers

Rank Fund Capital Flow
1
Creative Planning
Creative Planning
Kansas
-$18K
2
Two Sigma Securities
Two Sigma Securities
New York
-$3.07K

CLRB Hedge Fund Activity: Q2 2018 in Review

12 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2018, worth a combined $426K — down 16% from $505K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CLRB positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $98.2K. The largest seller was Creative Planning, exiting entirely with an estimated $18K sold.

  • 12 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2018, up from 10 in Q1 2018.
  • Funds reported $426K of Cellectar Biosciences stock for Q2 2018, down 16% quarter-over-quarter.
  • 3 funds opened new Cellectar Biosciences positions in Q2 2018 and 1 closed out, a net change of +2 holders.
  • The largest Cellectar Biosciences buyer in Q2 2018 was Virtu Financial, an estimated $98.2K added.
  • The largest Cellectar Biosciences seller in Q2 2018 was Creative Planning, an estimated $18K sold.

Based on aggregated 13F filings for Q2 2018.